NR2F1 and melanoma: Dormancy and drug tolerance have been linked to resistance and disease relapse in melanoma (15, 16, 53–55); therefore, we questioned whether NR2F1 contributes to BRAFi + MEKi tolerance and the persistence of MRD burden.